Natalie Dickson, MD, president and chief strategy officer of Tennessee Oncology, discusses Tennessee Oncology's role in the discussion to reform 340B.
Tennessee Oncology believes treating and managing patients regardless of whether they're insured is the right thing to do, said Natalie Dickson, MD, president and chief strategy officer of Tennessee Oncology.
Transcript:
How has Tennessee Oncology led the discussion to reform 340B and responded to the challenge the program presents for community oncology?
The 340B program was developed to help patients in need, and especially those patients with cancer. Unfortunately, it has been determined that, by and large, hospitals have not increased their uncompensated care once they've entered this 340B program.
Tennessee Oncology continues to be the primary provider of free cancer care in our market, and we treat and manage all patients who grace our clinics, regardless of whether they're insured or not. We think it's just the right thing to do.
What we can do is that we can continue to advocate for fair pricing and for price transparency. We'll also try to make data available to health policy researchers. We will continue to demonstrate our value, so demonstrate our value proposition to our patients in our communities, health plans, and the employers. Our value proposition is that we provide the highest quality of care with the lowest cost for drugs, for radiation, for imaging, for labs, and we continue to provide cutting-edge clinical research and comprehensive supportive care services for our patients close to their homes. I think it's in the best interest for patients, health plans, and employers to shift all expensive treatments from the hospital to the community, and if we share our data and share our experiences, I think this may accelerate this transition.
The Impact of Cost-Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
As Claims Denials Surge, AI and Data-Driven Insights Equip Clinicians, Hospitals to Fight Back
March 13th 2025As health care costs continue to rise and the burden of chronic disease grows, data-driven insights will be essential in shaping the future of patient care, according to experts from Komodo Health and SmarterDx.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More